UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

FORM 8-K

CURRENT REPORT
Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): August 4, 2008

ARIAD Pharmaceuticals, Inc.
(Exact name of registrant as specified in its charter)

Delaware

0-21696

22-3106987

(State or other jurisdiction

of incorporation)

(Commission

File Number)

(I.R.S. Employer

Identification No.)

26 Landsdowne Street, Cambridge, Massachusetts	02139
(Address of principal executive offices)	(Zip Code)

Registrant's telephone number, including area code: (617) 494-0400

Not Applicable
(Former name or former address, if changed since last report)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):

⃞ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

⃞ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

⃞ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

⃞ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

In a press release dated August 7, 2008, ARIAD Pharmaceuticals, Inc. (the “Company”) announced financial results for the second quarter and six months ended June 30, 2008. The information set forth in the first two paragraphs of the press release, under the heading “Financial Highlights” and in the attached financial tables is being furnished pursuant to this Item 2.02 of this Current Report on Form 8-K.

ITEM 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.

(b) On August 4, 2008, Richard W. Pascoe advised the Company that he was resigning his position as senior vice president and chief operating officer of ARIAD. The resignation is effective on August 8, 2008. Mr. Pascoe has accepted the position of chief executive officer of a specialty pharmaceutical company focused on psychiatric and neurological diseases.

ITEM 7.01 Regulation FD Disclosure.

In the press release dated August 7, 2008, the Company provided financial guidance for the year ending December 31, 2008 and provided information on upcoming medical and investor meetings. The information set forth under the headings “Financial Guidance”, “Upcoming Medical Meeting” and “Upcoming Investor Meetings” is being furnished pursuant to this Item 7.01 of this Current Report on Form 8-K.

ITEM 8.01 Other Events.

In the press release dated August 7, 2008, the Company provided an update on progress of its development programs and changes in its senior management team under the headings “Progress in the Clinic” and “Changes in Senior Management Team,” respectively. The Company hereby incorporates such information by reference into this Item 8.01 of this Current Report on Form 8-K.

Exhibit
Number	Description

99.1	Press release dated August 7, 2008.

The portion of the press release incorporated by reference into Item 8.01 of this Current Report on Form 8-K is being filed pursuant to Item 8.01. In accordance with General Instruction B.2. to Form 8-K, the remaining portions of the press release are being furnished and shall not be deemed “filed” for purposes of Section 18 of the Securities and Exchange Act of 1934 (the “Exchange Act”) or otherwise subject to the liabilities of that Section, nor shall it be deemed incorporated by reference in any filing under the Securities Act of 1933 or the Exchange Act.

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

		ARIAD Pharmaceuticals, Inc.

Date:	August 7, 2008	By:	/s/ Edward M. Fitzgerald
			Edward M. Fitzgerald
			Senior Vice President, Chief Financial Officer